Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2019 Dec 18;14(12):e0226427. doi: 10.1371/journal.pone.0226427

Chronic atrophic gastritis and intestinal metaplasia surrounding diffuse-type gastric cancer: Are they just bystanders in the process of carcinogenesis?

Seung Yong Shin 1,2, Jie-Hyun Kim 2,*, Jaeyoung Chun 2, Young Hoon Yoon 2, Hyojin Park 2
Editor: Dajun Deng3
PMCID: PMC6919620  PMID: 31851694

Abstract

Background

Gastric cancer (GC) is categorized as diffuse- and intestinal-type adenocarcinoma. Intestinal-type GC is associated with chronic gastritis, atrophic gastritis (AG), and intestinal metaplasia (IM), precursors of dysplastic changes. Diffuse-type GC is generally known to undergo de novo carcinogenesis and is not associated with chronic mucosal changes. However, clinically, AG and IM are frequently observed surrounding diffuse-type GC. This study aimed to evaluate the role of AG and IM in diffuse-type GC.

Methods

We retrospectively reviewed the data of patients undergoing surgery for early GC. We divided patients with diffuse-type GC into two groups according to the presence of AG and IM based on Kyoto classification of gastritis. The clinicopathological characteristics were compared between the groups.

Results

Among patients with diffuse-type GC, 52.5% patients had AG and 18.4% had severe AG. With regard to IM, 42.1% patients had IM and 17.1% had severe IM. Diffuse-type GC combined with severe AG or IM showed larger tumor size and higher submucosal invasion rate than that without severe AG or IM. However, the lymph node metastasis (LNM) rate was not significantly different between the two groups. In multivariate analysis, severe AG or IM was not an independent risk factor for LNM.

Conclusions

Severe AG or IM surrounding diffuse-type gastric cancer suggests a collapse of normal mucosal barriers and leads to the spread of cancer cells. Although the association between chronic mucosal changes and LNM is unclear, more caution is needed during endoscopy especially for complete resection of diffuse-type GC with these features.

Introduction

Gastric cancer (GC) is classified into two major histological subtypes, diffuse-type and intestinal-type adenocarcinoma, according to the Lauren classification [1]. The differences in epidemiology, pathogenesis, and morphological appearance between these two GC types have been widely accepted [1,2]. Diffuse-type GCs are often reported in young patients, are known to be highly metastatic, and show more rapid progression and poor prognosis when compared with intestinal-type GCs [3,4]. In terms of carcinogenesis, intestinal-type GC is more likely to be associated with Helicobacter pylori (H. pylori) infection. The stepwise mucosal changes initiated by H. pylori infection are considered to be a major step in the carcinogenic cascade of intestinal-type GC [5,6], and atrophic gastritis (AG) and intestinal metaplasia (IM) are suggested to be the typical chronic mucosal changes in this cascade [7–9]. AG is characterized by multifocal loss of the original gastric glands, including mucus-secreting glands comprising parietal and chief cells. AG has been suggested to be the first histopathological lesion in intestinal-type GC [10,11]. IM is characterized by the appearance of glands with an intestinal phenotype that can be combined with multifocal atrophies involving the gastric mucosa. As atrophic and metaplastic glands replace the normal gastric glands, the number of normal gastric glands decreases, and precancerous processes such as dysplasia are initiated.

Carcinogenesis in diffuse-type GC is different from that in intestinal-type GC. A defined series of preneoplastic mucosal changes or precancerous lesions are not usually found in diffuse-type GC. Less well differentiated, non-glandular formations, with an occasional presence of signet ring cells, are the pathological characteristics of diffuse-type GC [12]. However, it is relatively common to find background mucosa in association with AG or IM surrounding diffuse-type GC in a clinical setting during diagnostic endoscopy (Fig 1). Some diffuse-type GCs are surrounded by these chronic mucosal changes, similar to that in intestinal-type GC. Although pathological evaluation was considered to be the gold standard diagnostic modality for AG and IM, recent studies have reported that endoscopic diagnosis of these chronic mucosal changes is also useful for identifying patients at risk of developing GC [13,14]. As chronic mucosal changes account for a large proportion of cases of carcinogenesis in intestinal-type GC, we wished to investigate the implications of chronic mucosal changes surrounding diffuse-type GC noted during endoscopy. It is necessary to determine how these chronic mucosal changes, which are precancerous lesions in intestinal-type GC, affect progression in diffuse-type GC for further understanding of carcinogenesis in diffuse-type GC. Therefore, this study aimed to identify the role of AG and IM surrounding diffuse-type GC.

Fig 1. Clinical cases of pathologically confirmed diffuse-type early gastric cancer (arrow).

Fig 1

Open in a new tab

On endoscopic evaluation, (A) atrophic gastritis and (B) intestinal metaplasia are observed in the surrounding mucosa.

Methods

Study design

This study evaluated 808 consecutive patients who underwent surgery for the treatment of early gastric cancer (EGC) at Gangnam Severance Hospital, Seoul, Korea. We collected the medical records and endoscopic images of patients who were diagnosed with EGC. Patients without preoperative endoscopic images were excluded from this study. Furthermore, patients in whom it was difficult to evaluate AG or IM owing to low resolution or insufficient images were excluded. Finally, 451 patients with diffuse-type GC were enrolled. The intestinal-type GC group was randomly selected from the remaining study cohort to compare their clinicopathological features with those of the diffuse-type GC group. We analyzed the clinicopathological data and endoscopic images. This study protocol was approved by the Institutional Review Board of Gangnam Severance Hospital (3-2019-0006) and was carried out in accordance with the 1964 Declaration of Helsinki and its later amendments. Informed consent was not required as this study was a retrospective analysis of existing administrative and clinical data.

Endoscopic image review

All endoscopic images with unanalyzed clinicopathological data of patients enrolled during the study period were collected and reanalyzed. AG and IM were categorized according to the Kyoto classification of gastritis, proposed at the 85th Congress of the Japan Gastroenterological Endoscopy Society for standardizing endoscopic findings of gastritis [15]. This classification allows grading of endoscopically visible AG and IM. AG is assessed by the Kimura-Takemoto classification (Close (C)-1, C-II, C-II; Open (O)-I, O-II, and O-III), and classified into three grades (none, C0-C1; mild, CII-CIII; and severe, OI-OIII)[16]. IM is also classified into three grades (none: none, mild: within the antrum, and severe: up to the corpus). In our study, two experienced gastrointestinal endoscopists re-examined all endoscopic images in the same manner and categorized AG and IM. They arrived at a consensus on this categorization through regular meetings.

Clinicopathological evaluation

The medical records of patients, including their clinicopathological characteristics, were reviewed by specialists who were blinded to the endoscopic findings. Pathological review was performed based on reports of surgical specimens. The gross appearance of the tumors was classified using the criteria of the Japanese Gastric Cancer Association, and the tumors were classified into two groups accordingly. Protruding type (Type I) and superficially elevated type (Type IIa) tumors were classified as elevated and the other types of tumor as non-elevated. Longitudinal tumor location was defined as being in the upper (fundus, cardia, and upper body), middle (mid-body, lower body, and the angle), and lower (antrum, prepylorus, and pylorus) stomach. Tumor size was measured using the longest and shortest diameters. The depth of tumor invasion was categorized as mucosal invasion (M), submucosal invasion of 500 μm or less from the muscularis mucosae (SM1), and submucosal invasion of more than 500 μm from the muscularis mucosae (SM2). Lymphovascular invasion (LVI), perineural invasion (PNI), and lymph node metastasis (LNM) were also identified. The clinicopathological features were compared between the severe AG or IM group and none-to-moderate AG or IM group.

Statistical analysis

For categorical variables, a Pearson chi-square test was used. Student t-test was used to compare the means of continuous variables, and continuous variables are presented as the mean ± standard deviation (SD). Variables that were significant in univariate analysis were subsequently tested by multivariate logistic regression analysis. Irrespective of the results of the univariate analysis, variables that could potentially influence the results were included in multivariate analysis. For all comparisons, two-sided P-values <0.05 were considered statistically significant. Statistical analyses were performed using SPSS version 18.0 (SPSS, Chicago, IL).

Results

Clinicopathological characteristics of intestinal-type and diffuse-type gastric cancer

Table 1 summarizes the clinicopathological characteristics of intestinal- and diffuse-type GCs. Diffuse-type GC, defined according to Lauren classification, included poorly differentiated adenocarcinoma (n = 204, 45.3%), signet ring cell carcinoma (SRC) (n = 245, 54.3%), and mucinous adenocarcinoma (n = 2, 0.4%). Patients with diffuse-type GC were younger and included a higher proportion of females than patients with intestinal-type GC. Intestinal-type GC showed a more elevated appearance and was more frequently located in the lower stomach. Severe IM was identified significantly more often in intestinal-type GC patients (30.5% vs. 17.3%, P < 0.001). Among patients with diffuse-type GC, 52.5% had AG and 18.4% had severe AG. In terms of IM, 42.1% patients had IM and 17.1% had severe IM in the group with diffuse-type GC. Diffuse-type GC was more commonly found to be confined to the mucosal layer in contrast to intestinal-type GC. LVI, PNI, and LNM rates were not significantly different between the two types of GCs.

Table 1. Clinicopathological characteristics of intestinal- and diffuse-type gastric cancers.

Diffuse-type
GC (n = 451)		 Intestinal-type
GC (n = 210)		 P value
Age (years, mean ± SD) 56.88 ± 12.49 62.94 ± 10.83 <0.001
Male (n, %) 229 (50.8) 151 (71.9) <0.001
Pathological findings (n, %)
    Well-differentiated adenocarcinoma 99 (47.1)
    Moderately differentiated adenocarcinoma 111 (52.9)
    Poorly differentiated adenocarcinoma 204 (45.3) -
    Signet ring cell carcinoma 245 (54.3) -
    Mucinous adenocarcinoma 2 (0.4) -
Kyoto classification 0.659
    Atrophic gastritis (n, %) 0.528
    None to mild 368 (81.6) 167 (79.5)
    Severe 83 (18.4) 43 (20.5)
Intestinal metaplasia (n, %) <0.001
    None to mild 373 (82.7) 146 (69.5)
    Severe 78 (17.3) 64 (30.5)
H. pylori infection (n, %) 206 (45.8) 152 (73.4) <0.001
Longitudinal location (n, %) 0.009
    Lower 272 (60.3) 150 (71.4)
    Mid 141 (31.3) 42 (20.0)
    Upper 38 (8.4) 18 (8.6)
Gross appearance (n, %) <0.001
    Elevated 67 (14.9) 62 (29.5)
    Non-elevated 384 (85.1) 148 (70.5)
Depth of invasion (n, %) 0.031
    M 259 (57.4) 99 (47.1)
    SM1 (≤500 μm) 40 (8.9) 28 (13.3)
    SM2 (≥500 μm) 152 (33.7) 83 (39.5)
LVI (n, %) 55 (12.2) 16 (7.6) 0.075
PNI (n, %) 15 (3.3) 5 (2.4) 0.509
LNM (n, %) 38 (8.4) 9 (4.3) 0.054
Open in a new tab

H. pylori, Helicobacter pylori; M, mucosa; SM, submucosa; LVI, lymphovascular invasion; PNI, perineural invasion; LNM, lymph node metastasis; GC, gastric cancer

Comparison between diffuse-type gastric cancer with and without severe atrophic gastritis

According to the severity of AG defined by Kyoto classification, patients with diffuse-type GC were divided into the severe and non-severe AG groups. Table 2 shows the clinicopathological features of the two groups. Diffuse-type GC with severe AG was frequently found in older patients. The tumor size was larger (longest diameter, 3.671 ± 2.543 cm vs. 2.659 ± 1.762, P = 0.001; shortest diameter, 2.551 ± 1.654 cm vs. 1.948 ± 1.740 cm, P = 0.006) and the rates of SM invasion and LVI were higher in the severe AG group than in the non-severe AG group. However, the LNM rate was not significantly different between the groups. In multivariate analysis, severe AG was not an independent risk factor for LNM (Table 3).

Table 2. Comparison between diffuse-type gastric cancer with and without severe atrophic gastritis.

Without
severe atrophic gastritis
(n = 368)		 With
severe atrophic gastritis
(n = 83)		 P value
Age (years, mean ± SD) 53.17 ± 12.17 63.29 ± 10.51 <0.001
Male (n, %) 183 (49.7) 46 (55.4) 0.349
H. pylori infection (n, %) 125 (33.9) 27 (32.5) 0.307
Longitudinal location (n, %) 0.354
    Lower 219 (59.5) 53 (63.9)
    Mid 120 (32.6) 21 (25.3)
    Upper 29 (7.9) 9 (10.8)
Gross appearance (n, %) 0.362
    Elevated 52 (14.1) 15 (18.1)
    Non-elevated 316 (85.9) 68 (81.9)
Depth of invasion (n, %) 0.001
    M 225 (61.1) 34 (41.0)
    SM 143 (38.9) 49 (59.0)
Size (cm, mean ± SD)
    Longest diameter 2.659 ± 1.762 3.671 ± 2.543 0.001
    Shortest diameter 1.948 ± 1.740 2.551 ± 1.654 0.006
LVI (n, %) 34 (9.3) 21 (25.3) <0.001
PNI (n, %) 10 (2.7) 5 (6.0) 0.129
LNM (n, %) 30 (8.2) 8 (9.6) 0.660
Open in a new tab

H. pylori, Helicobacter pylori; M, mucosa; SM, submucosa; LVI, lymphovascular invasion; PNI, perineural invasion; LNM, lymph node metastasis

Table 3. Multivariate analysis of clinicopathological characteristics associated with LNM in diffuse-type gastric cancer.

Odds ratio (95% confidence interval) P value
Severe atrophic gastritis 0.069
    No Reference
    Yes 0.381 (0.134–1.080)
Severe intestinal metaplasia 0.833
    No Reference
    Yes 1.112 (0.416–2.975)
Tumor size 0.023
    ≤2 cm Reference
    >2 cm 2.985 (1.165–7.647)
Depth of invasion 0.004
    M Reference
    SM 5.586 (1.576–17.803)
LVI <0.001
    No Reference
    Yes 10.073 (4.219–24.053)
PNI 0.229
    No Reference
    Yes 2.237 (0.602–8.318)
Open in a new tab

LNM, lymph node metastasis; M, mucosa; SM, submucosa; LVI, lymphovascular invasion; PNI, perineural invasion

Comparison between diffuse-type gastric cancer with and without severe intestinal metaplasia

Patients with diffuse-type GC were also divided according to the severity of IM as defined by Kyoto classification into the severe and non-severe IM groups (Table 4). Upon comparing the two groups, older age and male sex were commonly associated with severe IM. The tumor size was larger in the severe IM group than in the non-severe IM group (longest diameter, 3.488 ± 2.657 cm vs. 2.725 ± 1.764 cm, P = 0.002; shortest diameter (cm), 2.449 ± 1.628 cm vs 1.973 ± 1.752 cm, P = 0.032). However, the depth of invasion, LVI, PNI, and LNM showed no significant differences between the groups. In multivariate analysis, severe IM was not found to be an independent risk factor for LNM (Table 3).

Table 4. Comparison between diffuse-type gastric cancer with and without severe intestinal metaplasia.

Without
severe intestinal metaplasia
(n = 373)		 With
severe intestinal metaplasia
(n = 78)		 P value
Age (years, mean ± SD) 53.83 ± 12.43 60.73 ± 11.32 <0.001
Male (n, %) 178 (47.8) 49 (63.6) 0.012
H. pylori infection (n, %) 127(34.0) 25 (32.1) 0.191
Longitudinal location (n, %) 0.648
    Lower 226 (60.5) 46 (58.4)
    Mid 114 (3.6) 27 (35.1)
    Upper 33 (8.9) 5 (6.5)
Gross appearance (n, %) 0.858
    Elevated 55 (14.8) 12 (15.6)
    Non-elevated 318 (85.2) 66 (84.4)
Depth of invasion (n, %) 0.263
    M 219 (58.9) 40 (51.9)
    SM 154 (41.1) 38 (59.0)
Size (cm, mean ± SD)
    Longest diameter 2.725 ± 1.764 3.488 ± 2.657 0.002
    Shortest diameter 1.973 ± 1.752 2.449 ± 1.628 0.032
LVI (n, %) 40 (10.8) 15 (19.5) 0.054
PNI (n, %) 12 (3.2) 3 (3.9) 0.766
LNM (n, %) 29 (7.8) 9 (11.7) 0.264
Open in a new tab

H. pylori, Helicobacter pylori; M, mucosa; SM, submucosa; LVI, lymphovascular invasion; PNI, perineural invasion; LNM, lymph node metastasis

Discussion

In accordance with previous studies, diffuse-type GC was associated with younger age and female sex compared with intestinal-type GC in our study [17,18]. Older patients and IM were significantly more common among those with intestinal-type GC. AG was also more frequently observed in intestinal-type GC, although the difference was not statistically significant. Intestinal-type GC showed more elevated lesions and was commonly located at a lower location, which is in accordance with previous findings [17]. Our study was unable to demonstrate a higher rate of SM invasion in diffuse-type GC than in intestinal-type GC. A possible explanation for this might be the relatively higher proportion (54.3%) of SRC cases in our study, which is known to be associated with a low incidence of SM invasion [18].

Severe AG and IM were noted in approximately 20% patients with diffuse-type GC during diagnostic endoscopy. We limited the comparison to that between severe AG or IM and others to minimize interobserver or intraobserver variation during endoscopic evaluation of AG or IM. Older patients more commonly showed these chronic mucosal changes. Chronic mucosal changes resulting from H. pylori infection are involved in the carcinogenesis of intestinal-type GC. In this study, patients with intestinal-type GC showed a higher infection rate of H. pylori compared to those with diffuse-type GC. H. pylori infection induces a chronic inflammatory reaction in the gastric mucosa, which causes atrophic changes or transformation of the glandular gastric epidermis to intestinal-type epithelium. The alkaline environment caused by these chronic mucosal changes facilitates the proliferation of H. pylori, which in turn leads to cell turnover increase and accumulation of mitotic errors resulting in cancerous changes of the gastric mucosa [19–21]. The higher infection rate of H. pylori in intestinal-type GC is thought to be associated with this carcinogenic cascade. Diffuse-type GC has widely been believed to arise from the mucosa without chronic mucosal changes, and shows no precancerous lesions. Therefore, endoscopists tend to presumably diagnose cancerous lesions with background chronic mucosal changes as intestinal-type GC based on diagnostic endoscopy. However, our study showed that cases with diffuse-type GC arising from background mucosa with AG or IM are more common than expected. A previous Japanese study demonstrated that endoscopic findings in patients with undifferentiated adenocarcinoma diagnosed according to the Japanese Classification of Gastric Carcinoma (14th edition) showed the presence of severe AG in 21.8% and severe IM in 19.4% patients [22]. They also suggested ambiguous glandular duct architecture, venous invasion, and reddish lesions as characteristic endoscopic findings in undifferentiated adenocarcinomas with severe AG [22]. Another study evaluating the background mucosa in patients with GC during diagnostic endoscopy found that open-type AG according to the Kimura-Takemoto classification is present in many patients with undifferentiated adenocarcinoma [23]. Our findings support the results of these previous studies. The incidence of severe AG and IM in diffuse type-GC may be explained by the increasing prevalence of AG and IM with age, as well as H. pylori infection [24], as the mean age of patients with severe AG or IM was higher than that of patients with non-severe AG or IM in our study. Thus, not only intestinal-type GC but also diffuse-type GC can arise from background mucosa with severe AG or IM. Therefore, a more careful and non-prejudiced approach is needed for evaluating lesions with these chronic mucosal changes during endoscopy. However, there is no previous study on whether these chronic mucosal changes are associated with aging or play any meaningful role in diffuse-type GC. Thus, we attempted to investigate the role of chronic mucosal changes surrounding diffuse-type GC in this study.

Compared with the non-severe AG group, the severe AG group showed a larger tumor size and higher SM invasion and LVI rates. The tumor size was also larger in the severe IM group compared to that in the non-severe IM group. A previous study demonstrated that the tumor size is larger in patients with undifferentiated-type GC with severe AG than in those with undifferentiated-type GC with mild-to-moderate AG [22]. The reason for the increase in tumor size when associated with severe AG or IM is uncertain. However, cancer cells seem to spread more easily in both horizontal and vertical directions when the background mucosa shows AG or IM. A possible explanation for these pathological findings is assumed to be the fact that the surrounding mucosa acts as a mechanical barrier to the spread of cancer cells in diffuse-type GC.

In terms of the barrier function of the mucosa, previous studies have reported that a diverse group of transmembrane proteins maintain the epithelial barrier function against pathogens. Tight junction proteins are present on the apical end of the lateral membrane surface in columnar epithelial cells and function as a barrier [25,26]. Although scarce data exist on the physiology or function of this barrier, barrier dysfunction is suggested to be a risk factor for cancer development in association with H. pylori infection [27]. The concept of mechanical barriers related to the spreading of cancer cells was reported in a study on SRC [28]. The surrounding mucosal pattern differs according to the manner in which the tumor spreads, and cells in SRC tend to spread diffusely into the subepithelial area in the presence of background mucosa with AG or IM. The authors further suggested that if the mechanical barrier represented by the surrounding mucosa is weak, such as in cases with AG or IM, cancer cells tend to spread sporadically or diffusely into the deeper layers of the mucosa. In addition, the status of the surrounding mucosa is suggested to be a predictive factor of intramucosal spreading patterns in SRC. In line with this, our study demonstrated that the disrupted mucosal barriers, as seen in cases with severe AG or IM, allow the cancer cells in diffuse-type GC to spread more easily in both horizontal and vertical directions. The fact that metachronous cancer occurs more frequently in cases with diffuse-type GC is also thought to be associated with AG or IM [29]. AG or IM, which suggests weakening of the mechanical barrier, can facilitate sporadic spreading of cancer cells. Thus, more careful assessment is required in patients with diffuse-type GC with severe AG or IM, especially when performing endoscopic resection as well as diagnostic endoscopy.

One interesting finding of our study is that the LNM rate showed no significant differences between the severe AG or IM and non-severe groups. A previous study investigating SRC showed similar results to those shown in our study [28]. Although the weakening of the mechanical barrier induced by AG or IM combined with diffuse-type GC is associated with the spreading of cancer cells into the mucosa and allows the tumor to increase in size or show LVI, it does not seem to have a significant effect on the prognosis of patients. Severe AG or IM affects the tumor size and SM invasion; however, it was not an independent risk factor of LNM. Although the exact reason for this finding remains unclear, a possible explanation for this might be that AG and IM themselves do not directly affect LNM, but the risk of LNM is increased owing to changes in the spreading pattern of cancer cells caused by these chronic mucosal changes. In other words, AG or IM in diffuse-type GC do not influence the aggressive behavior of cancer, but rather provide an environment in which the cancer cells spread more aggressively. Validation of our findings with a large-scale study is needed to gain further insight.

A previous Japanese study demonstrated that most intestinal-type GCs occur in association with severe AG or IM, whereas diffuse-type GCs occur predominantly at the atrophic border which is characterized by active inflammation. These authors suggested that active inflammation may cause DNA damage in gastric epithelial cells [30]. Several studies have also suggested genetic abnormalities in cell adhesion factors, rather than chronic mucosal changes, as the cause of diffuse-type GC [31–34]; our study supports this notion. In contrast to its role as a precancerous lesion in the carcinogenesis of intestinal-type GCs, AG or IM in diffuse-type GCs may play a role related to the mechanical barrier function of the mucosa, which is not associated with carcinogenesis.

This study has several limitations. Firstly, it was a retrospective, single-center study. Secondly, interobserver bias may exist given that this study was performed based on a review of endoscopic images. However, endoscopists applied the same criteria for the endoscopic review and reached consensus through periodic meetings. To the best of our knowledge, this is the first study to evaluate the role of AG or IM in diffuse-type GC. Further large-scale studies are needed to validate our results.

In conclusion, AG or IM surrounding diffuse-type GC suggests the destruction of the normal mechanical barrier that prevents the spread of cancer cells. Although these chronic mucosal changes may not play a role in the process of carcinogenesis in diffuse-type GC, in contrast to their role in intestinal-type GC, more careful assessment is needed in cases with diffuse-type GC during endoscopy, especially in order to achieve a complete endoscopic resection.

Supporting information

S1 File. Data set.

(XLSX)

Click here for additional data file. (97.3MB, xlsx)

Acknowledgments

The English in this document has been checked by at least two professional editors, both native speakers of English (www.editage.co.kr).

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This study was financially supported by the "SEBANG" Faculty Research Assistance Program of Yonsei University College of Medicine (6-2014-0191). This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2018R1A2B6008139).

References

  • 1.Lauren P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965;64: 31–49 10.1111/apm.1965.64.1.31 [DOI] [PubMed] [Google Scholar]
  • 2.Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17: 2693–2701. 10.1158/1078-0432.CCR-10-2203 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012;30: 3507–3515. 10.1200/JCO.2011.35.8028 [DOI] [PubMed] [Google Scholar]
  • 4.Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008;135: 41–60. 10.1053/j.gastro.2008.05.030 [DOI] [PubMed] [Google Scholar]
  • 5.Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52: 6735–6740 [PubMed] [Google Scholar]
  • 6.Sipponen P, Kekki M, Siurala M. Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma. Comparison with a representative population sample. Cancer. 1983;52: 1062–1068 [DOI] [PubMed] [Google Scholar]
  • 7.Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345: 784–789. 10.1056/NEJMoa001999 [DOI] [PubMed] [Google Scholar]
  • 8.Satoh K, Osawa H, Yoshizawa M, Nakano H, Hirasawa T, Kihira K, et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter. 2008;13: 225–229. 10.1111/j.1523-5378.2008.00599.x [DOI] [PubMed] [Google Scholar]
  • 9.Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71: 1150–1158. 10.1016/j.gie.2009.12.029 [DOI] [PubMed] [Google Scholar]
  • 10.Tsugane S, Kabuto M, Imai H, Gey F, Tei Y, Hanaoka T, et al. Helicobacter pylori, dietary factors, and atrophic gastritis in five Japanese populations with different gastric cancer mortality. Cancer Causes Control. 1993;4: 297–305 10.1007/bf00051331 [DOI] [PubMed] [Google Scholar]
  • 11.Azuma T, Ito S, Sato F, Yamazaki Y, Miyaji H, Ito Y, et al. The role of the HLA-DQA1 gene in resistance to atrophic gastritis and gastric adenocarcinoma induced by Helicobacter pylori infection. Cancer. 1998;82: 1013–1018 [DOI] [PubMed] [Google Scholar]
  • 12.Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer. 2000;89: 1418–1424 [PubMed] [Google Scholar]
  • 13.Sugimoto M, Ban H, Ichikawa H, Sahara S, Otsuka T, Inatomi O, et al. Efficacy of the Kyoto Classification of Gastritis in Identifying Patients at High Risk for Gastric Cancer. Intern Med. 2017;56: 579–586. 10.2169/internalmedicine.56.7775 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Koike K. Association between gastric cancer and the Kyoto classification of gastritis. J Gastroenterol Hepatol. 2017;32: 1581–1586. 10.1111/jgh.13764 [DOI] [PubMed] [Google Scholar]
  • 15.Kamada T, Haruma K, Inoue K, Shiotani A. [Helicobacter pylori infection and endoscopic gastritis -Kyoto classification of gastritis]. Nihon Shokakibyo Gakkai Zasshi. 2015;112: 982–993. 10.11405/nisshoshi.112.982 [DOI] [PubMed] [Google Scholar]
  • 16.Kimura K, Satoh K, Ido K, Taniguchi Y, Takimoto T, Takemoto T. Gastritis in the Japanese stomach. Scand J Gastroenterol Suppl. 1996;214: 17–20; discussion 21–13 10.3109/00365529609094509 [DOI] [PubMed] [Google Scholar]
  • 17.Lee JY, Gong EJ, Chung EJ, Park HW, Bae SE, Kim EH, et al. The Characteristics and Prognosis of Diffuse-Type Early Gastric Cancer Diagnosed during Health Check-Ups. Gut Liver. 2017;11: 807–812. 10.5009/gnl17033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Lee SH, Jee SR, Kim JH, Seol SY. Intramucosal gastric cancer: the rate of lymph node metastasis in signet ring cell carcinoma is as low as that in well-differentiated adenocarcinoma. Eur J Gastroenterol Hepatol. 2015;27: 170–174. 10.1097/MEG.0000000000000258 [DOI] [PubMed] [Google Scholar]
  • 19.Asaka M, Takeda H, Sugiyama T, Kato M. What role does Helicobacter pylori play in gastric cancer? Gastroenterology. 1997;113: S56–60. 10.1016/s0016-5085(97)80013-3 [DOI] [PubMed] [Google Scholar]
  • 20.Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet. 1975;2: 58–60. 10.1016/s0140-6736(75)90498-5 [DOI] [PubMed] [Google Scholar]
  • 21.El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 1997;113: 15–24. 10.1016/s0016-5085(97)70075-1 [DOI] [PubMed] [Google Scholar]
  • 22.Kishino M, Nakamura S, Shiratori K. Clinical and Endoscopic Features of Undifferentiated Gastric Cancer in Patients with Severe Atrophic Gastritis. Intern Med. 2016;55: 857–862. 10.2169/internalmedicine.55.4841 [DOI] [PubMed] [Google Scholar]
  • 23.Inoue K, Fujisawa T, Chinuki D, Kushiyama Y. Characteristics of gastric mucosa in gastric cancer improvement-examination from a clinical survey by endoscopy. Stomach and Intestine. 2009;44: 1367–1373 [Google Scholar]
  • 24.Kim HJ, Choi BY, Byun TJ, Eun CS, Song KS, Kim YS, et al. [The prevalence of atrophic gastritis and intestinal metaplasia according to gender, age and Helicobacter pylori infection in a rural population]. J Prev Med Public Health. 2008;41: 373–379. 10.3961/jpmph.2008.41.6.373 [DOI] [PubMed] [Google Scholar]
  • 25.Tsukita S, Furuse M. Pores in the wall: claudins constitute tight junction strands containing aqueous pores. J Cell Biol. 2000;149: 13–16 10.1083/jcb.149.1.13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Tsukita S, Furuse M. The structure and function of claudins, cell adhesion molecules at tight junctions. Ann N Y Acad Sci. 2000;915: 129–135 10.1111/j.1749-6632.2000.tb05235.x [DOI] [PubMed] [Google Scholar]
  • 27.Caron TJ, Scott KE, Fox JG, Hagen SJ. Tight junction disruption: Helicobacter pylori and dysregulation of the gastric mucosal barrier. World J Gastroenterol. 2015;21: 11411–11427. 10.3748/wjg.v21.i40.11411 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Kim H, Kim JH, Lee YC, Kim H, Youn YH, Park H, et al. Growth Patterns of Signet Ring Cell Carcinoma of the Stomach for Endoscopic Resection. Gut Liver. 2015;9: 720–726. 10.5009/gnl14203 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Seo JH, Park JC, Kim YJ, Shin SK, Lee YC, Lee SK. Undifferentiated histology after endoscopic resection may predict synchronous and metachronous occurrence of early gastric cancer. Digestion. 2010;81: 35–42. 10.1159/000235921 [DOI] [PubMed] [Google Scholar]
  • 30.Yoshimura T, Shimoyama T, Fukuda S, Tanaka M, Axon AT, Munakata A. Most gastric cancer occurs on the distal side of the endoscopic atrophic border. Scand J Gastroenterol. 1999;34: 1077–1081. 10.1080/003655299750024850 [DOI] [PubMed] [Google Scholar]
  • 31.Cho SY, Park JW, Liu Y, Park YS, Kim JH, Yang H, et al. Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. Gastroenterology. 2017;153: 536–549.e526. 10.1053/j.gastro.2017.05.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet. 2000;26: 16–17. 10.1038/79120 [DOI] [PubMed] [Google Scholar]
  • 33.Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46: 583–587. 10.1038/ng.2984 [DOI] [PubMed] [Google Scholar]
  • 34.Ghatak S, Chakraborty P, Sarkar SR, Chowdhury B, Bhaumik A, Kumar NS. Novel APC gene mutations associated with protein alteration in diffuse type gastric cancer. BMC Med Genet. 2017;18: 61 10.1186/s12881-017-0427-2 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Dajun Deng

30 Sep 2019

PONE-D-19-16075

Chronic atrophic gastritis and intestinal metaplasia surrounding diffuse-type gastric cancer: Are they just bystanders in the process of carcinogenesis?

PLOS ONE

Dear Dr. Kim,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Nov 14 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Dajun Deng, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript by Shin et al entitled “Chronic atrophic gastritis and intestinal metaplasia surrounding diffuse-type gastric cancer: Are they just bystanders in the process of carcinogenesis?” evaluated the role and meaning of atrophic gastritis (AG) and intestinal metaplasia (IM) in diffuse-type GC. They demonstrated that diffuse-type GC combined with severe AG or IM showed larger tumor size and higher submucosal invasion rate than that without severe AG or IM. But the multivariate analysis showed that severe AG or IM was not an independent risk factor for LNM. Overall, this topic is interesting. I have the following minor concerns:

1. In Table 1, the authors mentioned that the intestinal type gastric cancer had higher infection rates with H. pylori. Can the authors include some studies in the discussion to explore the possible mechanism?

2. Diffuse-type GC combined with severe AG or IM showed larger tumor size and higher submucosal invasion rate than that without severe AG or IM. But the multivariate analysis showed that severe AG or IM was not an independent risk factor for LNM. What do the authors think might be the reasons? In Line 244, the authors stated that “Although the weakening of mechanical barrier induced by AG or IM combined with diffuse-type GC is associated with the spreading of cancer cells into the mucosa and allows the tumor to increase in size or to invade LVI, it does not seem to have a significant effect on the prognosis of patients.” But they did not explain this phenomenon.

3. In Line 247, the authors stated that “In contrast to its role as a precancerous lesion in the carcinogenesis of intestinal-type GCs, AG or IM in diffuse-type GCs may play a role related to a mechanical barrier, which is not associated with carcinogenesis.” Do the authors mean that AG or IM in diffuse-type GCs can destroy the normal barrier to protect the spread of tumor cells? Meanwhile, can the authors provide some evidences to demonstrated that AG or IM in diffuse-type GCs is not associated with carcinogenesis?

4. In Line 257, the authors stated that “In conclusion, AG or IM surrounding diffuse-type GC suggests the destruction of normal mechanical barriers that protect the spread of cancer cells.” But in Table 2, the result showed that with or without severe AG was not associated with LNM rates. Why?

5. English editing is recommended.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2019 Dec 18;14(12):e0226427. doi: 10.1371/journal.pone.0226427.r002

Author response to Decision Letter 0

16 Nov 2019

Reviewer #1

The manuscript by Shin et al entitled “Chronic atrophic gastritis and intestinal metaplasia surrounding diffuse-type gastric cancer: Are they just bystanders in the process of carcinogenesis?” evaluated the role and meaning of atrophic gastritis (AG) and intestinal metaplasia (IM) in diffuse-type GC. They demonstrated that diffuse-type GC combined with severe AG or IM showed larger tumor size and higher submucosal invasion rate than that without severe AG or IM. But the multivariate analysis showed that severe AG or IM was not an independent risk factor for LNM. Overall, this topic is interesting. I have the following minor concerns.

1. In Table 1, the authors mentioned that the intestinal type gastric cancer had higher infection rates with H. pylori. Can the authors include some studies in the discussion to explore the possible mechanism?

Response> Thank you for your valuable comments. As reviewer commented, we have included some studies in the discussion to explore the possible mechanisms. The higher infection rate of H. pylori in intestinal-type GC is thought to be associated with carcinogenesis of GC. Previous studies have suggested that the chronic inflammatory reactions to the gastric mucosa caused by H. pylori infection induce atrophic changes or mucosal transformation to intestinal-type epithelium, and facilitate the proliferation of H. pylori in an environment of hypochlorhydria. When this process continues, cell turnover increases and mitotic errors accumulates which result in cancerous changes of gastric mucosa. We presented the additional comments in the discussion. The details of the changes are as follows:

(Discussion section, page 15, line 214): “In this study, patients with intestinal-type GC showed a higher infection rate of H. pylori compared to those with diffuse-type GC. H. pylori infection induces a chronic inflammatory reaction in the gastric mucosa, which causes atrophic changes or transformation of the glandular gastric epidermis to intestinal-type epithelium. The alkaline environment caused by these chronic mucosal changes facilitates the proliferation of H. pylori, which in turn leads to cell turnover increase and accumulation of mitotic errors resulting in cancerous changes of the gastric mucosa [19-21]. The higher infection rate of H. pylori in intestinal-type GC is thought to be associated with this carcinogenic cascade.”

2. Diffuse-type GC combined with severe AG or IM showed larger tumor size and higher submucosal invasion rate than that without severe AG or IM. But the multivariate analysis showed that severe AG or IM was not an independent risk factor for LNM. What do the authors think might be the reasons? In Line 244, the authors stated that “Although the weakening of mechanical barrier induced by AG or IM combined with diffuse-type GC is associated with the spreading of cancer cells into the mucosa and allows the tumor to increase in size or to invade LVI, it does not seem to have a significant effect on the prognosis of patients.” But they did not explain this phenomenon.

Response> Thank you for your valuable comments. The aim of this study was to determine whether the presence of AG or IM in the diffuse-type GC affects the biologic behavior such as LNM. The results showed that the diffuse-type GC surrounded by AG or IM had larger tumor size and deeper invasion depth, but in multivariate analysis, AG or IM did not affect LNM. Therefore, it can be interpreted that the increased risk of LNM is not attributed to AG or IM itself, but to the changed spreading pattern caused by AG or IM. AG or IM destroys the normal mechanical barrier and allows cancer cells to spread more easily in both horizontal and vertical direction which leads to increasing LNM risk. In other words, the meaning of AG or IM in diffuse-type GC is not itself affecting the aggressive behavior of cancer, but rather providing an environment in which the cancer cells more aggressively spread. However, validation with large scale study is needed. We presented the additional comments regarding this concern in the discussion. The details of the changes are included in the answers to the question 4.

3. In Line 247, the authors stated that “In contrast to its role as a precancerous lesion in the carcinogenesis of intestinal-type GCs, AG or IM in diffuse-type GCs may play a role related to a mechanical barrier, which is not associated with carcinogenesis.” Do the authors mean that AG or IM in diffuse-type GCs can destroy the normal barrier to protect the spread of tumor cells? Meanwhile, can the authors provide some evidences to demonstrated that AG or IM in diffuse-type GCs is not associated with carcinogenesis?

Response > Thank you for your valuable comments. As we mentioned in discussion section, barrier dysfunction of normal mucosa is suggested to be a risk factor for cancer development in association with H. pylori infection, and the concept of mechanical barriers related to the spreading of cancer cells was reported in a previous study of SRC. We also have suggested the role of normal mucosa as a mechanical barrier for protecting tumor cell spread. Chronic mucosal changes are the destruction of normal glandular structures which means the collapse of mucosal barriers. Regarding evidences to demonstrate that AG or IM in diffuse-type GCs is not associated with carcinogenesis, we have provided evidences related to the differences of carcinogenesis between intestinal-type and diffuse-type GC. Although genetic factors, gastric environment, and Helicobacter pylori infection have been associated with the pathogenicity and development of intestinal-type GC that follows the Correa’s cascade, the pathogenicity of diffuse-type GC remains mostly unknown and undefined. Previous Japanese study showed that most intestinal-type GC occurs distal to the atrophic border, where severe atrophic gastric mucosa and intestinal metaplasia has been present for a longer period. However, they found that diffuse-type arises close to the atrophic border, and suggested that the active element of inflammation, which is predominantly in the region of the atrophic border, may damage DNA in gastric epithelial cells (Yoshimura T et al. Scand J Gastroenterol. 1999 Nov;34(11):1077-81). Although underlying molecular pathways have not yet been well-studied and understood, genetic abnormalities in the cell adherence factors such as E-cadherin, and cellular activities that cause impaired cell integrity and physiology have been suggested and documented as contributing factors of diffuse-type GC rather than chronic mucosal changes (Cho SY et al. Gastroenterology. 2017 Aug;153(2):536-549.e26, Ghatak S etl al. BMC Med Genet. 2017 Jun 2;18(1):61, Kakiuchi M et al. Nat Genet. 2014 Jun;46(6):583-7). We presented the additional comments regarding this concern in the discussion. The details of the changes are as follows:

(Discussion section, page 18, line 290): “A previous Japanese study demonstrated that most intestinal-type GCs occur in association with severe AG or IM, whereas diffuse-type GCs occur predominantly at the atrophic border which is characterized by active inflammation. These authors suggested that active inflammation may cause DNA damage in gastric epithelial cells [30]. Several studies have also suggested genetic abnormalities in cell adhesion factors, rather than chronic mucosal changes, as the cause of diffuse-type GC [31-34]; our study supports this notion.”

4. In Line 257, the authors stated that “In conclusion, AG or IM surrounding diffuse-type GC suggests the destruction of normal mechanical barriers that protect the spread of cancer cells.” But in Table 2, the result showed that with or without severe AG was not associated with LNM rates. Why?

Response > Thank you for your valuable comments. The possible explanation for this might be that AG and IM themselves do not directly affect the LNM, but the risk of LNM can be increased due to changes in the spreading patterns of cancer cell caused by these chronic mucosal changes. Cancer cells are able to spread more easily toward both the horizontal and vertical sides when the background mucosa shows AG or IM. Therefore, the role of AG and IM surrounding diffuse-type GC are limited to the destruction of the normal mechanical barrier, not affect directly on LNM or any process of carcinogenesis. However, careful assessments are required in AG and IM surrounding diffuse-type GC in that they affect the spreading patterns of the cancer cell which are directly associated with LNM. Further studies are warranted to better understand severe mucosal changes and LNM in diffuse-type GC. We presented the additional comments regarding this concern in the discussion. The details of the changes are as follows:

(Discussion section, page 18, line 281): “Severe AG or IM affects the tumor size and SM invasion; however, it was not an independent risk factor of LNM. Although the exact reason for this finding remains unclear, a possible explanation for this might be that AG and IM themselves do not directly affect LNM, but the risk of LNM is increased owing to changes in the spreading pattern of cancer cells caused by these chronic mucosal changes. In other words, AG or IM in diffuse-type GC do not influence the aggressive behavior of cancer, but rather provide an environment in which the cancer cells spread more aggressively. Validation of our findings with a large-scale study is needed to gain further insight.”

5. English editing is recommended

Response> Thank you for your kind comment. The English has been checked by at least two professional editors. We presented the additional comments regarding English editing.

(Page 20, Acknowledgements, line 341): “The English in this document has been checked by at least two professional editors, both native speakers of English.”

Thank you for all your valuable comments above. We think the editors’ comments have significantly improved the quality of our manuscript by guiding our insights appropriately.

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file. (29KB, docx)

Decision Letter 1

Dajun Deng

27 Nov 2019

Chronic atrophic gastritis and intestinal metaplasia surrounding diffuse-type gastric cancer: Are they just bystanders in the process of carcinogenesis?

PONE-D-19-16075R1

Dear Dr. Kim,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Dajun Deng, M.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Dajun Deng

10 Dec 2019

PONE-D-19-16075R1

Chronic atrophic gastritis and intestinal metaplasia surrounding diffuse-type gastric cancer: Are they just bystanders in the process of carcinogenesis?

Dear Dr. Kim:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Dajun Deng

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Data set.

    (XLSX)

    Click here for additional data file. (97.3MB, xlsx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    Click here for additional data file. (29KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES